NasdaqGM - Delayed Quote • USD
Affimed N.V. (AFMD)
At close: May 14 at 4:00 PM EDT
After hours: May 14 at 6:33 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -1.69 | -1.3 | -4.99 | -4 |
| Low Estimate | -1.94 | -1.63 | -6.6 | -5.41 |
| High Estimate | -1.59 | -0.75 | -3.3 | -2.65 |
| Year Ago EPS | -2.26 | -2.15 | -7.64 | -4.99 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 6 |
| Avg. Estimate | 920k | 770k | 4.54M | 5.5M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 2.25M | 2.25M | 10.77M | 11.09M |
| Year Ago Sales | 5.06M | 1.47M | 8.91M | 4.54M |
| Sales Growth (year/est) | -81.80% | -47.60% | -49.10% | 21.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.11 | -2.04 | -1.99 | -1.66 |
| EPS Actual | -2.26 | -2.15 | -1.72 | -1.45 |
| Difference | -0.15 | -0.11 | 0.27 | 0.21 |
| Surprise % | -7.10% | -5.40% | 13.60% | 12.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.69 | -1.3 | -4.99 | -4 |
| 7 Days Ago | -1.69 | -1.4 | -5.26 | -3.8 |
| 30 Days Ago | -1.68 | -1.39 | -5.21 | -3.77 |
| 60 Days Ago | -1.45 | -1.34 | -6.23 | -5.35 |
| 90 Days Ago | -0.15 | -0.14 | -0.61 | -0.57 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AFMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.20% | -- | -- | 7.30% |
| Next Qtr. | 39.50% | -- | -- | 10.90% |
| Current Year | 34.70% | -- | -- | 4.60% |
| Next Year | 19.80% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 10.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/25/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/12/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Maintains | Truist Securities: Buy to Buy | 8/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
Related Tickers
ADAP Adaptimmune Therapeutics plc
1.1500
-1.71%
PRQR ProQR Therapeutics N.V.
1.9850
+0.25%
SGMO Sangamo Therapeutics, Inc.
0.5679
+2.99%
CLRB Cellectar Biosciences, Inc.
3.1800
+3.92%
LVTX LAVA Therapeutics N.V.
2.8900
-5.56%
PIRS Pieris Pharmaceuticals, Inc.
11.22
+0.09%
AVRO AVROBIO, Inc.
1.2900
-4.44%
NXTC NextCure, Inc.
1.5900
-0.62%
ACHL Achilles Therapeutics plc
0.9200
+3.94%
KPTI Karyopharm Therapeutics Inc.
1.0900
-2.68%